Does TOFACITINIB Cause Stent placement? 61 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 61 reports of Stent placement have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.0% of all adverse event reports for TOFACITINIB.
61
Reports of Stent placement with TOFACITINIB
0.0%
of all TOFACITINIB reports
25
Deaths
43
Hospitalizations
How Dangerous Is Stent placement From TOFACITINIB?
Of the 61 reports, 25 (41.0%) resulted in death, 43 (70.5%) required hospitalization, and 38 (62.3%) were considered life-threatening.
Is Stent placement Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 61 reports have been filed with the FAERS database.
What Other Side Effects Does TOFACITINIB Cause?
Drug ineffective (30,382)
Pain (21,659)
Condition aggravated (16,925)
Arthralgia (15,640)
Fatigue (13,551)
Rheumatoid arthritis (12,277)
Off label use (11,736)
Headache (11,061)
Joint swelling (10,686)
Malaise (9,040)
What Other Drugs Cause Stent placement?
RANOLAZINE (593)
EVOLOCUMAB (244)
ADALIMUMAB (227)
ROSIGLITAZONE (196)
ETANERCEPT (174)
CLOPIDOGREL BISULFATE (167)
RIVAROXABAN (122)
ASPIRIN (118)
APIXABAN (116)
MACITENTAN (108)
Which TOFACITINIB Alternatives Have Lower Stent placement Risk?
TOFACITINIB vs TOFERSEN
TOFACITINIB vs TOLNAFTATE
TOFACITINIB vs TOLODODEKIN ALFA
TOFACITINIB vs TOLTERODINE
TOFACITINIB vs TOLVAPTAN